A randomized, double-blind, placebo- and active-controlled, parallel group, 6-week study to evaluate the effect of multiple doses of Flutiform [formoterol/fluticasone propionate] 250/10 microgram HFA [hydrofluoroalkane] pMDI [pressurised metered-dose inhaler] twice daily, Flutiform 100/10 microgram HFA pMDI twice daily, prednisone and placebo on the hypothalamic-pituitary-adrenal axis in adult subjects with mild to moderate asthma
Phase of Trial: Phase I
Latest Information Update: 30 Nov 2008
At a glance
- Drugs Formoterol/fluticasone propionate; Prednisone
- Indications Asthma
- Focus Pharmacodynamics
- Sponsors SkyePharma AG
- 30 Nov 2008 Status changed from active, no longer recruiting to completed, as reported on ClinicalTrials.gov.
- 18 Aug 2008 Planned end date changed from 1 Jul 2008 to 1 Sep 2008 as reported by ClinicalTrials.gov.
- 18 Aug 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.